



# Auro Laboratories Limited

314, T.V. Industrial Estate, S.K. Ahire Marg,  
Worli, Mumbai - 400 030, India  
Tel.: + 91 22 6663 5456  
Fax : +91 22 6663 5460  
E-mail : auro@aurolabs.com  
Web : www.aurolabs.com

---

Reg. Off. / Mfg. Unit :  
K-56, M. I. D. C. Tarapur,  
Dist. Palghar, Maharashtra - 401506.  
CIN No. L33125MH1989PLC051910

Date: May 29, 2018.

To  
The Deputy General Manager,  
**BSE Limited**  
PhirozeJeejeebhoy Towers,  
Dalal Street, Fort,  
**Mumbai - 400001.**

**Reg: Security Code No. 530233:**

**Sub: Outcome of Board Meeting Held on May 29, 2018.**

Dear Sir,

Pursuant to provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its Meeting held today i.e. May29,2018 inter-alia, considered following matters:

**Financial Results:**

Approved the Audited Financial Results of the Company for the quarter and year ended on 31<sup>st</sup> March, 2018.

Pursuant to provisions of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the following:

- a) Audited Standalone Financial Results for the quarter and year ended March 31, 2018 along with the Statement of Assets and Liabilities of the Company as on that date.
- b) Auditors Report on the Financial Results for the quarter and year ended March 31, 2018.
- c) Statement on Impact of Audit Qualifications(Modified Opinion) are enclosed herewith.

---

The Board of Directors has deferred the approval of Notice of AGM & Directors Report to the next Board Meeting.


The meeting of the Board of Directors commenced at 2.30 PM and concluded at 3.15 PM. The results will be published in the newspapers in terms of Regulation 47(1)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 in due course.

Kindly take the above on your record.

Thanking You.

Yours faithfully,

For AURO LABORATORIES LIMITED



**SHARAT DEORAH**  
**CHAIRMAN & MANAGING DIRECTOR**  
(DIN: 00230784)

**AURO LABORATORIES LIMITED**  
CIN NO. :- L33125MH1989PLC051910

Regd. Office : K - 56 M.I.D.C INDUSTRIAL AREA, TARAPUR  
BOISAR, DIST. PALGHAR 401506 , MAHARASHTRA

Tel.: +91-22-66635456 Fax:+91-22-66635460 Email. auro@aurolabs.com Web: www.aurolabs.com

**ANNEXURE - I**

<b>PART - I</b>						
<b>STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2018</b>						
Rs. In Lakhs						
Sr. No.	Particulars	3 Months ended	Preceding 3 Months ended	Corresponding 3 Months ended in the Previous Year	Year Ended	Previous Year Ended
		31.03.2018 (Audited)	31.12.2017 (Unaudited)	31.03.2017 (Audited)	31.03.2018 (Audited)	31.03.2017 (Audited)
<b>1</b>	<b>Income from Operations</b>					
	(a) Net Sales/Income from Operations (Net)	1127.82	1227.33	1007.32	4079.40	3,547.47
<b>2</b>	<b>Other Income</b>	22.65	12.34	19.94	51.39	53.41
<b>3</b>	<b>Total Revenue (1 + 2)</b>	<b>1,150.47</b>	<b>1,239.67</b>	<b>1,027.26</b>	<b>4,130.79</b>	<b>3,600.88</b>
<b>4</b>	<b>Expenses</b>					
	a. Consumption of raw material	660.79	586.79	476.14	2461.65	2,006.36
	b. Purchase of Stock-in-trade	1.24	1.98	0.51	4.06	1.31
	c. (Increase) / decrease in Finished Goods stock in trade and work in progress	(92.49)	210.75	-11.07	6.24	234.16
	d. Employee benefits expense	171.92	68.56	122.12	369.54	308.08
	e. Finance Cost	5.03	41.00	-16.46	108.85	107.26
	f. Depreciation and amortisation expenses	20.11	28.00	26.38	93.11	86.38
	g. Other Expenses	178.15	168.22	229.66	614.60	565.01
	<b>Total Expenses (4)</b>	<b>944.75</b>	<b>1,105.30</b>	<b>827.28</b>	<b>3,658.05</b>	<b>3,308.56</b>
<b>5</b>	<b>Profit / (Loss) before exceptional and extraordinary items and tax (3 ± 4)</b>	<b>205.72</b>	<b>134.38</b>	<b>199.98</b>	<b>472.74</b>	<b>292.32</b>
<b>6</b>	<b>Exceptional items</b>					
<b>7</b>	<b>Profit / (Loss) before extraordinary items and tax (5 ± 6)</b>	<b>205.72</b>	<b>134.38</b>	<b>199.98</b>	<b>472.74</b>	<b>292.32</b>
<b>8</b>	<b>Extraordinary Items</b>					
<b>9</b>	<b>Profit / (Loss) before tax (7 ± 8)</b>	<b>205.72</b>	<b>134.38</b>	<b>199.98</b>	<b>472.74</b>	<b>292.32</b>
<b>10</b>	<b>Tax expense</b>					
	(a) Current tax expenses for current year	-	-	-	127.34	58.82
	(b) MAT credit (where applicable)	-	-	-	-	-
	(c) Defferered tax	-	-	-	(7.56)	151.98
<b>11</b>	<b>Profit / (Loss) for the period from continuing operation (9± 10)</b>	<b>205.72</b>	<b>134.38</b>	<b>199.98</b>	<b>352.96</b>	<b>81.52</b>
<b>12</b>	<b>Profit / (Loss) for discontinuing operations</b>					
<b>13</b>	<b>Tax expense of discontinuing operations</b>					
<b>14</b>	<b>Profit / (Loss) for discontinuing operation (after tax) (12 ± 13)</b>	<b>205.72</b>	<b>134.38</b>	<b>199.98</b>	<b>352.96</b>	<b>81.52</b>
<b>15</b>	<b>Other Comprehensive Income</b>	<b>2.75</b>	<b>(1.81)</b>	<b>1.12</b>	<b>4.63</b>	<b>1.12</b>
<b>16</b>	<b>Total Comprehensive Income for the period (14 ± 15)</b>	<b>208.47</b>	<b>132.57</b>	<b>201.10</b>	<b>357.59</b>	<b>82.64</b>
<b>17</b>	<b>Paid-up equity share capital</b>	<b>623.25</b>	<b>623.25</b>	<b>623.25</b>	<b>623.25</b>	<b>623.25</b>
	(Face value of Rs. 10 each)					
<b>18</b>	<b>Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year</b>				<b>251.30</b>	<b>173.59</b>
<b>19</b>	<b>Earnings per share (EPS) (Face Value - Rs. 10 per Equity Shares):</b>					
	(a) Basic	3.30	2.16	3.21	5.66	1.31
	(b) Diluted	3.30	2.16	3.21	5.66	1.31


FOR & BEHALF OF BOARD OF DIRECTORS  
AURO LABORATORIES LIMITED

SHARAT DEORAH  
CHAIRMAN & MANAGING DIRECTOR.  
DIN NO. 00230784

Place : Mumbai  
Date : 29.05.2018

## Auro Laboratories Limited

## Statement of Assets and Liabilities (Ind AS)

Particulars		(Rs. In Lakh)		
		As at 31/03/2018	As at 31/03/2017	As at 01/04/2016
		Audited	Audited	Audited
<b>A</b>	<b>ASSETS</b>			
	<b>1. Non-Current Assets</b>			
	(a) Property, Plant and Equipment	1,302.33	1300.02	913.06
	(b) Capital Work -in-Progress	107.29	22.62	333.12
	(c) Investment Property	-	0.00	0.00
	(d) Financial Assets			
	(i) Investments	4.88	4.88	4.88
	(ii) Loans	-	-	-
	(iii) Others	-	-	-
	(e) Other non-current assets - Capital Advance	-	-	-
	<b>2. Current assets</b>			
	(a) Inventories	149.10	132.58	430.89
	(b) Financial Assets			
	(i) Investments	-	-	-
	(ii) Trade Receivables	837.49	768.79	505.84
	(iii) Cash and cash equivalents	179.74	49.77	5.21
	(iv) Bank balances other than (iii) above	45.27	50.75	47.99
	(v) Loans	-	-	-
	(vi) Others	414.24	351.04	329.69
	(c) Other Current Assets	-	-	-
	<b>TOTAL ASSETS</b>	<b>3040.34</b>	<b>2680.45</b>	<b>2570.68</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>			
	<b>1. Equity</b>			
	(a) Equity Share Capital	623.25	623.25	623.25
	(b) Other Equity	674.52	318.05	240.34
	<b>2. Liabilities</b>			
	(I) Non-Current Liabilities			
	(a) Financial Liabilities			
	(i) Other Financial Liabilities	617.84	494.97	539.12
	(b) Provisions	302.00	493.30	723.28
	(c) Deferred Tax Liabilities (Net)	144.41	151.98	-
	(II) Current Liabilities			
	(a) Financial Liabilities			
	(i) Trade Payables	530.11	492.65	354.48
	(b) Other Current Liabilities	73.28	66.15	56.39
	(c) Provisions	74.93	40.09	33.82
	(d) Current Tax Liabilities (net)	-	-	-
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>3040.34</b>	<b>2680.45</b>	<b>2570.68</b>
FOR & BEHALF OF BOARD OF DIRECTORS AURO LABORATORIES LIMITED				
				
SHARAT DEORAH CHAIRMAN & MANAGING DIRECTOR. DIN NO. 00230784				
Place : Mumbai Date : 29.05.2018				

**AURO LABORATORIES LIMITED**


**Notes:**

- 1) The Company had adopted Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder. The date of transition to Ind AS is 1st April, 2017 and accordingly these audited financial results have been prepared in accordance with recognition and measurement principles laid down in Ind. AS 34 "Interim Financial Reporting" and the other accounting principles generally accepted in India. The impact of transition had been accounted for in the opening reserves and comparative period figures have been reinstated accordingly.
- 2) The Audited financial results were reviewed by the Audit Committee and their after approved by the Board of Directors at meeting held on 29th May 2018.
- 3) Figures of last quarter are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the current financial year
- 4) The Company operates in single segment i.e. "Pharmaceuticals", and hence does not have any additional disclosures to be made under Ind As 108 on operating Segments.
- 6) Figures of previous period have regrouped / reclassified wherever necessary to facilitate comparison.
- 7) There is a possibility that these quarterly financial results may require adjustment before constituting the Final Ind AS financial statements as on the year ending March 31, 2018 due to changes in financial reporting requirements arising from new or revised standards or interpretations issued by MCA or changes in the use of one or more optional exemptions from full retrospective application as permitted under Ind AS 101.
- 8) The reconciliation of Net Profit reported in accordance with Indian GAAP to total comprehensive income in accordance with Ind. AS for the Quarter and year ended is as under.

Particulars	Rs. In Lacs	
	for the qtr. ended 31.03.2017	for the year ended 31.03.2017
Profit / (Loss) under previous GAAP	199.98	81.52
Ind. AS adjustment:		
Profit / (Loss) on Investment measure at fair value	-	-
<b>Profit / (Loss) under Indian AS</b>	199.98	81.52
Other Comprehensive Income	1.12	1.12
<b>Total Comprehensive Income for the period</b>	<b>201.10</b>	<b>82.64</b>

FOR & BEHALF OF BOARD OF DIRECTORS

AURO LABORATORIES LIMITED

  
SHARAT DEORA

CHAIRMAN & MANAGING DIRECTOR.

DIN NO. 00230784

Place : Mumbai

Date : 29.05.2018



**KHURDIA JAIN & CO.**  
CHARTERED ACCOUNTANTS

**Independent Auditor's Report on standalone financial results of the company pursuant to the regulation 33 of the SEBI (Listing obligation and Disclosure Requirements) Regulation, 2015.**

**To**


**The Board of Directors of,  
AURO LABORATORIES LIMITED,**

We have audited standalone financial result of AURO LABORATORIES LIMITED ("The Company"), for the year ended 31<sup>st</sup> March 2018 (the financial results), attached herewith, being submitted by the company pursuant to the requirement of regulation 33 of the SEBI (Listing Obligations and disclosure requirements) Regulations 2015. The financial results are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such financial statements, which have been prepared in accordance under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India.

We conduct our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit include examining, on test basis, evidence supporting the amounts disclose as financial results, An audit also included assessing the accounting principal used and significant estimate made by the management, we believe that our audit provides a reasonable basis our opinion.

In our opinion and to the best of ours information and according to the explanation given to us these financial results:

- i. Are presented in accordance with the requirements of regulations 33 of the SEBI (Listing Obligation and disclosure Requirements) Regulations, 2015; and
- ii. Give a true and fair view of the net profit and other financial information for the year ended 31<sup>st</sup> March 2018.





**KHURDIA JAIN & CO.**  
CHARTERED ACCOUNTANTS


Attention is Invite to:


- i. Note no 4 of the accompanied financial results regarding non provision for doubtful loans and advances of Rs.7,49,633/- resulting to overstatement of profit amounting of Rs. 7,49,633/- for the year

Our opinion is not modified in respect of above matter.

The Financial results include the results for the quarter ended 31<sup>st</sup> March 2018 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For KHURDIA JAIN & CO  
CHARTERED ACCOUNTANTS  
FIRM REGN. NO. 120263 W

  
[SAMPAT KHURDIA]  
PARTNER  
M.NO. 033615



Place: Mumbai

Date: 29<sup>th</sup> MAY 2018

**ANNEXURE I**

**Statement on Impact of Audit Qualifications (for audit report with modified opinion) submitted along-  
with Annual Audited Financial Results - (Standalone and Consolidated separately)**

Statement on Impact of Audit Qualifications for the Financial Year ended March 31, 2018[See Regulation 33 / 52 of the SEBI (LODR) (Amendment) Regulations, 2016]				
I	Sl. NO.	Particulars	Audited Figures (as reported before adjusting for qualifications)	Adjusted Figures (audited figures after adjusting for qualifications)
	1.	Turnover / Total income		
	2.	Total Expenditure	413079028	413079028
	3.	Net Profit/(Loss)	365805899	366555532
	4.	Earnings Per Share	47273129	46523496
	5.	Total Assets	7.58	7.46
	6.	Total Liabilities	304034827	303285194
	7.	Net Worth	304034827	303285194
	8.	Any other financial item(s) (as felt appropriate by the management)	129777138	129027505
			-	-
<p><b>II. Audit Qualification (each audit qualification separately):</b></p> <p>a) Details of Audit Qualification: 1) Doubtful loans and advances</p> <p>b) Type of Audit Qualification : Qualified Opinion / Disclaimer of Opinion / Adverse Opinion</p> <p>c) Frequency of qualification: Whether appeared first time / repetitive / since how Long continuing : More than 6 Years</p> <p>d) For Audit Qualification(s) where the impact is quantified by the auditor, Management's Views: Yes</p> <p>e) For Audit Qualification(s) where the impact is not quantified by the auditor:</p> <p>(i) Management's estimation on the impact of audit qualification:</p> <p>(ii) If management is unable to estimate the impact, reasons for the same:</p> <p>(iii) Auditors' Comments on (i) or (ii) above: N . A.</p>				

*DM*



III. **Signatories:**

• **Sharat Deorah**  
Managing Director

S D D D

• **Amit Shah**  
CFO

A m s h

• **Khurdia Jain & Company**  
Sampat Khurdia  
Auditor of the company

Sampat Khurdia

• **Kailash Chandra Bubna**  
Audit Committee Chairman

K C B

**Place: Mumbai**  
**Date: 29.05.2018**